Evie Jackson

61 posts

Evie Jackson

Evie Jackson

@evierjackson

Postdoctoral Research Fellow, Medical Biochemistry | uon/hmri | DIPG/DMG | #DunLab | https://t.co/SVidKmNpql

Newcastle, NSW Katılım Mayıs 2020
69 Takip Edilen106 Takipçiler
Evie Jackson
Evie Jackson@evierjackson·
I'm so honoured to be named a Col Reynolds ECR Fellow for 2024. Congrats to fellow recipients and huge thank you to @KidsCancerProj for their support. Also thank you to the support from the #DunLab as well as @MattDun17 and @duchatel_ryan. @PrecisionMedUON @UON_research
The Kids' Cancer Project@KidsCancerProj

The Kids’ Cancer Project has committed over $7.6 million to support 24 of Australia’s top young scientists. Watch the full video and learn more about the 2023 and 2024 cohort of Col Reynolds Fellows. brnw.ch/21wLZbY

English
2
1
12
1.4K
Evie Jackson retweetledi
Matt Dun, PhD
Matt Dun, PhD@MattDun17·
Ph #DunLab! So proud of @evierjackson graduating today! Our 1st incredible #DIPG #DMG student but nowhere near our last. Enjoy EJ and thanks for your dedication, leadership and excellence. Thanks @_IsabellaMarcus for EJ scholarship and to all our supporters and parents @RUNDIPG
Matt Dun, PhD tweet mediaMatt Dun, PhD tweet media
English
0
5
44
2.7K
Evie Jackson
Evie Jackson@evierjackson·
Here, we describe a clinically relevant combination therapy and highlight the inclusion of RT. Our results also provide the impetus for future studies targeting alterations to myelination and the immune environment due to combined paxalisib and enzastaurin. (11/13)
English
1
0
5
220
Evie Jackson
Evie Jackson@evierjackson·
Therefore, it is imperative to promote the benefit of radiation, our only current weapon against DIPG. Here, we treble the survival benefit of the combination by include RT, showing impressive tumor regression. (10/13)
Evie Jackson tweet media
English
1
0
6
183
Evie Jackson
Evie Jackson@evierjackson·
Through investigating the chromatin architecture (ATAC-seq), we further validated these findings, showing that the treatment driving this proinflammatory landscape, much like patients diagnosed with multiple sclerosis, which is unsurprising given the OPC cell of origin. (9/13)
Evie Jackson tweet media
English
1
0
5
192
Evie Jackson
Evie Jackson@evierjackson·
Additionally, we show genes critical to oligodendroglial myelination show significantly decreased expression in tumor tissue treatment with the combination, driving this proinflammatory landscape. (8/13)
Evie Jackson tweet media
English
1
0
4
157
Evie Jackson
Evie Jackson@evierjackson·
Here, we show increased TGFB1 and MHC II gene expression profiles, alongside increased STAT1 signaling, suggesting DIPG’s genetic dependence of PI3K signaling may promote immune escape through impacting antigen presentation. (7/13)
Evie Jackson tweet media
English
1
0
6
170
Evie Jackson
Evie Jackson@evierjackson·
Yet, although we show a synergistic survival benefit, mice still succumb of DIPG. Therefore, we assess therapeutic escape/plasticity via single cell spatial transcriptomics analysis using the @10xGenomics Xenium platform, showing high PDGFRA expression in tumor regions. (6/13)
Evie Jackson tweet media
English
1
2
11
1.4K
Evie Jackson
Evie Jackson@evierjackson·
We performed global unbiased quantitative phosphoproteomic profiling of DIPG cells treated with paxalisib, confirming potent PI3K/Akt/mTOR pathway inhibition, whilst simultaneously activating PKC signaling, ameliorated using the PKC inhibitor, enzastaurin. (5/13)
Evie Jackson tweet media
English
1
0
5
213
Evie Jackson
Evie Jackson@evierjackson·
In line with in vitro analysis, the phosphorylation of pAKT (Thr308/Ser473) decreased in a dose-dependent manner. Treatment with optimized dosing of 5 mg/kg/b.i.d. maintained suppression of PI3K signaling to a similar level to that of 10 mg/kg/day. (4/13)
Evie Jackson tweet media
English
1
0
4
160
Evie Jackson
Evie Jackson@evierjackson·
Treatment of DIPG cell line models with paxalisib potently inhibited PI3K/Akt/mTOR phosphorylation, sustained for up to 24h post-treatment in vitro. (3/13)
Evie Jackson tweet media
English
1
0
5
238
Evie Jackson
Evie Jackson@evierjackson·
DIPG cells lines were significantly more sensitive to paxalisib than non-midline high grade gliomas, with normal controls [HCMEC/D3 BBB endothelial cells, HMC3 microglial cells and ReN neural progenitor cells] resistant to treatment at high dose. (2/13)
Evie Jackson tweet media
English
1
0
5
331
Evie Jackson retweetledi
Sebastian Waszak
Sebastian Waszak@sebastianw·
The PNOC001 trial results on everolimus for children with progressive/recurrent pLGG and genomic biomarkers for progressive disease are now published in @JCO_ASCO ascopubs.org/doi/abs/10.120…. Congratulations to the @PNOC_kids team! @UCSF_PBC @NeurosurgUCSF @epflSV @NCMMnews @NeuroOnc
Journal of Clinical Oncology@JCO_ASCO

‼️ #SNO2023 simultaneous publication in #JCO by Mueller, et al: Everolimus for Children with Recurrent or Progressive Low-Grade Glioma: Results from the Phase 2 PNOC001 Trial. brnw.ch/21wEyjN

English
0
4
21
4.8K